

---

# MANAGEMENT OF ORAL ANTIHYPERGLYCEMIC MEDICATIONS DURING GENERAL HOSPITAL ADMISSION

MEREDITH VIGNEAUX, PHARMD, ASHLEY EVANS, PHARMD, BCACP, CHARLES LUNDAY, PHARMD



# CONFLICT OF INTEREST

- The speaker has no actual or potential conflict of interest in relation to this presentation

# ABOUT MERCY

- Founded by the Sisters of Mercy in 1891
- Springfield, Missouri
- 886 bed hospital
- Level I trauma, STEMI, and burn center
- Part of an integrated health system with 173 clinics in the Springfield Community, 50 of those clinics being primary care



---

# LEARNING OBJECTIVE

- 
- Recognize the impact of continuation or discontinuation of home oral antihyperglycemic medications (OAM) on inpatient glycemic management.

Continuation of home oral antihyperglycemic medications (OAM) puts patients at increased risk for experiencing glycemic events during hospital admission.

Hypoglycemia rates of 30-40% have been observed in patients continued on home OAM during hospital admission.<sup>3,5</sup>

The current practice at the study institution is to discontinue home OAM, unless reasonable to continue per clinician's judgement.

This study investigated glycemic safety in relation to home OAM continuation or discontinuation.

## BACKGROUND

# PRIMARY OBJECTIVE

Occurrence of composite glycemic events defined as:

Hyperglycemia is 2 blood glucose readings of  $>180$  mg/dL<sup>1,2</sup>

Level 1 Hypoglycemia is 1 blood glucose of  $<70$  mg/dL<sup>1</sup>

Level 2 Hypoglycemia is 1 blood glucose of  $<54$  mg/dL<sup>1</sup>

Level 3 Hypoglycemia is 1 blood glucose of  $<40$  mg/dL<sup>2</sup>

1. ADA Standards of Care 2020

2. Intensive versus Conventional Glucose Control in Critically Ill Patients The NICE-SUGAR Study Investigators

## SECONDARY OBJECTIVES

Occurrence of hyperglycemia

Occurrence of hypoglycemia

Length of hospital stay (LOS)

Use of glycemic medications

- Hyperglycemic medications: sliding scale insulin (SSI)
- Hypoglycemic medications: dextrose and glucagon

IRB approval on January 15th, 2020

125 patients in each group with a predicted glycemic event rate of 50% needed to achieve 90% power

Alpha was set at 0.05

Nieman Fisher test used for the primary objective

Retrospective chart review

## METHODS



OAM on home  
medication list



Age  $\geq$  18 years



Admitted to study  
institution from  
7/1/2017 to  
7/1/2019

## INCLUSION CRITERIA

Hypoglycemia  
upon  
admission

Admission  
diagnosis of  
DKA or HHS

Admitted for  
< 48 hours

Admission  
diagnosis of  
myocardial  
infarction


EXCLUSION  
CRITERIA

OAM continued within the first 48 hours of admission

OAM discontinued upon admission

DATA  
STRATIFICATION

# STUDY POPULATION



## BASELINE CHARACTERISTICS

Home OAM	Average Age (years)	Male (%)	Female (%)	Average BMI (kg/m <sup>2</sup> )	Average AIC (%)	Average LOS (days)	SSI Use (%)
Continued	68.2	53.6	46.4	32.5	7.8	5.7	60.1
Discontinued	66.2	53.5	46.5	34.9	8.1	6	85.8
P -Value	0.15	0.31	0.31	0.045	0.24	0.28	0.0001

# PRIMARY OBJECTIVE

## PRIMARY OBJECTIVE : COMPOSITE GLYCEMIC EVENTS

Continued = 76.8%

Discontinued = 76.3%


P value = 0.95

Not statistically significant

# SECONDARY OBJECTIVES




# INPATIENT GLYCEMIC EVENTS STRATIFIED BY TYPE




# LENGTH OF STAY IN DAYS

Length of Stay in Days



# USE OF RESCUE MEDICATIONS



# 01

The study did not reach *a priori* power.

There may be a difference in glycemic event rates after continuation versus discontinuation of home OAM that was not evident in the study population.

# 02

Under reporting of glycemic events due to inconsistent blood glucose monitoring during some admissions

# 03

Continuous ongoing improvement of glycemic safety by study institution

## LIMITATIONS

Low rates of hypoglycemia seen in the study suggest the current practice surrounding continuation or discontinuation of home OAM at the study institution is safe.

Further investigation would help better define glycemic management best practices.

## CONCLUSION

Role of pharmacist clinical judgment in continuation or discontinuation of home OAM at point of verification

Patient parameters associated with continuation or discontinuation of home OAM

Compliance with best practice alerts regarding glucose monitoring for safety

Impact of continuation or discontinuation of home OAM on the transitions of care process in relation to patient safety and adherence outcomes

Cost associated with SSI versus home OAM continuation

## AREAS FOR FUTURE INVESTIGATION

## RESOURCES

1. American Diabetes Association-Standards of Medical Care in Diabetes 2020.
2. Intensive versus Conventional Glucose Control in Critically Ill Patients The NICE-SUGAR Study Investigators. *n engl j med* 360;13 [nejm.org](http://nejm.org) march 26, 2009.
3. Lori M. Dickerson, PharmD,BCPS et al. Glycemic Control in Medical Inpatients with Type 2 Diabetes Mellitus Receiving Sliding Scale Insulin Regimens versus Routine Diabetes Medications: A Multicenter Randomized Controlled Trial. *Annals of Family Medicine* Vol. 1, No. 1 May/June 2003.
4. Thomas G. K. Breuer and Juris J. Meier. Inpatient Treatment of Type 2 Diabetes. *Deutsches Ärzteblatt International | Dtsch Arztebl Int* 2012; 109(26): 466–74
5. Yon Su Kim et al. Frequency and Severity of Hypoglycemia in Type 2 Diabetes Mellitus Patients Treated with a Sulfonylurea-Based Regimen at University-Affiliated Hospitals in Korea: The Naturalistic Evaluation of Hypoglycemic Events in Diabetic Subjects Study. *Korean J Fam Med*. 2019 Jul;40(4):212-219. doi: 10.4082/kjfm.18.0051. Epub 2019 Jul 20.

# CONTACT INFORMATION



Meredith Vigneaux, PharmD  
Mercy Hospital, Springfield, MO



Email:  
[Meredith.Vigneaux2@Mercy.net](mailto:Meredith.Vigneaux2@Mercy.net)



Phone: 417-820-4194





# QUESTIONS